Эта страница была переведена автоматически, точность перевода не гарантируется. Пожалуйста, обратитесь к английской версии для исходного текста.

Эндоваскулярная абляция правого большого чревного нерва у субъектов с HFpEF (Rebalance-HF)

16 сентября 2026 г. обновлено: Axon Therapies, Inc.

ЭНДОВАСКУЛЯРНАЯ АБЛАЦИЯ ПРАВОГО БОЛЬШОГО ЧРЕСТНОГО НЕРВА ПРИ ЭНДОВАСКУЛЯРНОЙ АБЛАЦИИ ПРАВОГО БОЛЬШОГО ЧРЕВСТВЕННОГО НЕРВА У Субъектов, страдающих HFpEF: технико-экономическое обоснование: рандомизированное контролируемое технико-экономическое исследование - исследование HF

The purpose of this clinical study is to evaluate the safety and early effectiveness of a catheter-based procedure that treats a nerve called the right greater splanchnic nerve. The study includes people who have heart failure with preserved ejection fraction (HFpEF). The goal is to learn whether this procedure, performed using the Satera Ablation System, may help improve symptoms and to better understand which patients may benefit most from this treatment in the future.

Обзор исследования

Статус

Рекрутинг

Условия

Вмешательство/лечение

Подробное описание

Up to 150 people will take part in this clinical study.

Phase I of the REBALANCE-HF Study

The first part of the study took place between January 2021 and March 2023. During this phase, 116 patients participated. Researchers reviewed the results to learn whether the procedure appeared safe and whether it might help improve symptoms in people with heart failure with preserved ejection fraction (HFpEF).

This early review showed encouraging results in some patients. It also helped researchers identify a group of patients who seemed more likely to benefit from the procedure.

Phase II of the REBALANCE-HF Study:

The current phase of the study focuses on patients who have similar characteristics to those who responded well in Phase I. The goal is to confirm whether this group of patients may benefit most from the treatment and whether the procedure should be studied further in a larger future trial.

This study will take place at multiple hospitals and research centers.

Participants who qualify for the study will be randomly assigned to one of two groups:

  • Treatment group: The procedure is performed using the Satera Ablation System to treat a nerve called the greater splanchnic nerve.
  • Control (sham) group: A simulated procedure is performed, but the treatment itself is not delivered.

Participants will be assigned to a group by chance, similar to flipping a coin, although twice as many patients will receive the treatment as the sham procedure (2:1 ratio).

The group assignment will happen during the procedure after anesthesia is given, and only after the doctor confirms that the patient's anatomy is suitable for the procedure.

Blinding:

To make sure the results are fair and unbiased:

  • Participants and their heart failure doctors will not know whether the patient received the treatment or the sham procedure.
  • The doctor performing the procedure and certain study staff will know which procedure is performed so they can carry out the procedure safely.
  • The study safety team will also know this information to help monitor patient safety.

Sham Procedure:

A sham procedure is used to help researchers understand whether any improvements are due to the treatment itself or to the placebo effect.

During the sham procedure:

A small needle puncture is made in the groin or neck, similar to what is done for many heart procedures.

Doctors check the veins to confirm whether the procedure could have been performed.

However, the treatment catheter is not used and the nerve is not treated.

The sham procedure takes about 45 minutes, which is about the same amount of time as the treatment procedure.

Number of Participants:

90 patients were assigned to treatment or sham during Phase I.

In Phase II, up to 60 additional patients will be enrolled.

About 40 patients will receive the treatment, and about 20 will receive the sham procedure.

Тип исследования

Интервенционный

Регистрация (Оцененный)

150

Фаза

  • Непригодный

Контакты и местонахождение

В этом разделе приведены контактные данные лиц, проводящих исследование, и информация о том, где проводится это исследование.

Контакты исследования

Учебное резервное копирование контактов

  • Имя: Desiree McFee, MS
  • Номер телефона: 6123568881
  • Электронная почта: desiree@axontherapies.com

Места учебы

  • Грузия
      • Tbilisi, Грузия
        • Рекрутинг
        • Tbilisi Heart and Vascular Center
        • Главный следователь:
          • Tamaz Shaburishvili, MD
        • Контакт:
      • Tbilisi, Грузия
        • Активный, не рекрутирующий
        • Tbilisi Heart Center
  • Соединенные Штаты
    • Alabama
      • Birmingham, Alabama, Соединенные Штаты, 35211
        • Завершенный
        • Cardiology PC
    • Arizona
      • Phoenix, Arizona, Соединенные Штаты, 85016
        • Завершенный
        • Arizona Cardiovascular Research Center
    • California
      • La Jolla, California, Соединенные Штаты, 92037
        • Рекрутинг
        • Scripps Health
        • Главный следователь:
          • Rajeev Mohan, MD
        • Главный следователь:
          • Matthew Price, MD
        • Контакт:
      • San Francisco, California, Соединенные Штаты, 94143
        • Рекрутинг
        • University of California, San Francisco
        • Главный следователь:
          • Liviu Klein, MD
        • Контакт:
      • San Francisco, California, Соединенные Штаты, 94143
        • Рекрутинг
        • Zuckerberg San Francisco General Hospital and Trauma Center
        • Контакт:
        • Главный следователь:
          • Lucas ZIer, MD
    • Georgia
      • Augusta, Georgia, Соединенные Штаты, 30901
        • Еще не набирают
        • Piedmont
        • Главный следователь:
          • Darshak Karia, MD
        • Контакт:
        • Контакт:
    • Illinois
      • Chicago, Illinois, Соединенные Штаты, 60611
        • Рекрутинг
        • Bluhm Cardiovascular Institute of Northwestern University
        • Главный следователь:
          • Ravi Patel, MD
        • Контакт:
      • Chicago, Illinois, Соединенные Штаты, 60637
        • Рекрутинг
        • University of Chicago Medical Center
        • Контакт:
        • Главный следователь:
          • Mark Nathan Belkin, MD
        • Контакт:
      • Springfield, Illinois, Соединенные Штаты, 62701
        • Завершенный
        • Prairie Education and Research Cooperative
    • Indiana
      • Indianapolis, Indiana, Соединенные Штаты, 46260
        • Завершенный
        • Ascension St. Vincent - Cardiovascular Research Institute
    • Louisiana
      • Houma, Louisiana, Соединенные Штаты, 70360
        • Рекрутинг
        • Cardiovascular Institute of the South
        • Главный следователь:
          • Peter Fail, MD
        • Контакт:
    • Michigan
      • Ann Arbor, Michigan, Соединенные Штаты, 48109
        • Рекрутинг
        • Michigan Medicine, University of Michigan
        • Главный следователь:
          • Scott Hummel, MD
        • Контакт:
    • Minnesota
      • Rochester, Minnesota, Соединенные Штаты, 55905
        • Рекрутинг
        • Mayo Clinic
        • Главный следователь:
          • Barry Borlaug, MD
        • Контакт:
    • Missouri
      • St Louis, Missouri, Соединенные Штаты, 63136
        • Рекрутинг
        • St. Louis Heart and Vascular
        • Главный следователь:
          • Gil Vardi, MD
        • Контакт:
    • New York
      • New York, New York, Соединенные Штаты, 10021
        • Рекрутинг
        • Weill Cornell Medicine
        • Главный следователь:
          • Parag Goyal, MD
        • Контакт:
      • New York, New York, Соединенные Штаты, 10032
        • Рекрутинг
        • Columbia University Medical Center
        • Главный следователь:
          • Nir Uriel, MD
        • Контакт:
      • New York, New York, Соединенные Штаты, 10029
        • Завершенный
        • Icahn School of Medicine at Mount Sinai
      • Rochester, New York, Соединенные Штаты, 14621
        • Рекрутинг
        • Rochester General Hospital
        • Контакт:
        • Главный следователь:
          • Vishal Parikh, DO
    • North Carolina
      • Durham, North Carolina, Соединенные Штаты, 27710
        • Рекрутинг
        • Duke University Medical Center
        • Главный следователь:
          • Marat Fudim, MD, MHS
        • Контакт:
    • Ohio
      • Cincinnati, Ohio, Соединенные Штаты, 45219
        • Еще не набирают
        • The Christ Hospital
        • Главный следователь:
          • Odayme Quesada, MD
        • Контакт:
      • Columbus, Ohio, Соединенные Штаты, 43210
        • Рекрутинг
        • Ohio State University Wexner Medical Center
        • Главный следователь:
          • Alexandria Miller, MD
        • Контакт:
    • South Carolina
      • Charleston, South Carolina, Соединенные Штаты, 29425
        • Рекрутинг
        • Medical University of South Carolina
        • Главный следователь:
          • Sheldon Litwin, MD
        • Контакт:
    • Texas
      • Houston, Texas, Соединенные Штаты, 77030
        • Рекрутинг
        • Baylor College of Medicine
        • Главный следователь:
          • Ajith Nair, MD
        • Контакт:
          • Claudell Montano
          • Номер телефона: 713-798-6832
          • Электронная почта: claudell.montano@bcm.edu
    • Virginia
      • Richmond, Virginia, Соединенные Штаты, 23298
        • Завершенный
        • Virginia Commonwealth University Medical Center

Критерии участия

Исследователи ищут людей, которые соответствуют определенному описанию, называемому критериям приемлемости. Некоторыми примерами этих критериев являются общее состояние здоровья человека или предшествующее лечение.

Критерии приемлемости

Возраст, подходящий для обучения

40 лет и старше (Взрослый, Пожилой взрослый)

Принимает здоровых добровольцев

Нет

Полы, имеющие право на обучение

Все

Описание

Inclusion Criteria

  1. Chronic heart failure, defined as:

    1. Symptoms of HF requiring current (intermittent or continuous) treatment with diuretics for >30 days, AND
    2. NYHA class II with a history of >NYHA class II in the past year, NYHA class III, or ambulatory NYHA class IV symptoms (paroxysmal nocturnal dyspnea, orthopnea, dyspnea on mild or moderate exertion) at screening or signs of HF (any rales post cough, chest x-ray demonstrating pulmonary congestion), AND
    3. At least one of the following:

    i. ≥1 HF hospital admission (with HF as the primary diagnosis) including treatment with intravenous (IV) diuretics or urgent unplanned treatment with IV diuretics in healthcare facility within past 12 months, OR ii. NT-proBNP >300 pg/ml in normal sinus rhythm (>450 pg/ml in atrial fibrillation or flutter) within the past 6 months; BNP >100 pg/ml in normal sinus rhythm (>300 pg/ml in atrial fibrillation or flutter) within the past 6 months, OR iii. Right heart catheterization (RHC) with PCWP ≥ with PCWP ≥18 mmHg at rest or 25 mmHg during exercise at the time of the screening RHC.

  2. Ongoing stable GDMT HF management (unless unable to tolerate GDMT) and management of potential comorbidities according to the 2022 ACCF/AHA Guideline for the Management of Heart Failure (Class 1 and 2a recommendations), with no significant changes [≥100% increase or ≥50% decrease] for a minimum of 1 month (30 days) prior to screening, that is expected to be maintained without change for at least 6 months. Participants cannot have started a glucagon-like peptide (GLP)-1 or gastric inhibitory peptide (GIP) agonist within the last 6 months or plan to start a GLP-1 or GIP agonist within the ensuing 6 months after enrollment.

  3. LVEF ≥50% (site-determined by transthoracic echocardiography) within the past 6 months.

  4. Age ≥40 years.

  5. Subject is willing and able to provide appropriate study-specific informed consent, follow protocol procedures, and comply with follow-up visit requirements.

Exclusion Criteria:

  1. MI (type I) and/or percutaneous cardiac intervention within 3 months prior to screening; CABG in past 3 months prior to screening, or current indication for coronary revascularization.

  2. Cardiac resynchronization therapy initiated within 3 months prior to screening.

  3. Advanced heart failure defined as one or more of the following:

    1. ACC/AHA/ESC Stage D HF or non-ambulatory NYHA Class IV HF.
    2. Inotropic infusion (continuous or intermittent) within 6 months prior to screening.
    3. Subject is on the cardiac transplant waiting list.
    4. Presence of or prior history of mechanical circulatory support for HF.

  4. Poor left heart compliance as determined by pulse-wave Doppler transmitral early-to-late (E/A) ratio >2.0 assessed by the screening echocardiogram. The Screening Committee will evaluate left heart function if the transmitral A velocity is not measurable or absent.

  5. Right heart dysfunction defined as tricuspid annular plane systolic excursion (TAPSE) <12 mm or right ventricular (RV) fractional area change (FAC) <25% assessed by the screening echocardiogram.

  6. Body mass index (BMI) >45 kg/m2.

  7. 6-minute walk test distance <100 meters OR >450 meters.

  8. Admission for HF within the 30 days prior to planned index procedure.

  9. Any known history of orthostatic hypotension or orthostatic hypotension at the time of screening (regardless of the presence of symptoms). Orthostatic hypotension is defined as a systolic blood pressure (BP) decrease of >20 mmHg upon going from supine to standing position or undergoing treatment with Midodrine.

  10. Orthostatic pulse pressure change from supine to standing decrease of >10mmHg in the absence of a HR increase >15bpm

  11. Postural orthostatic tachycardia syndrome or preload insufficiency syndrome.

  12. Systolic BP <100 mmHg or >170 mmHg despite appropriate medical management.

  13. Baseline screening ECG resting HR >100 beats per minute or ventricular tachycardia.

  14. Catheter ablation for atrial fibrillation within 6 months prior to screening or planned in the next 12 months at the time of screening.

  15. Left ventricular EF <40% within the 3 years prior to screening unless reduced EF was transient and associated with an acute event.

  16. Presence of significant valve disease defined by the site cardiologist as:

    1. Greater than mild mitral valve stenosis.
    2. Greater than moderate mitral valve regurgitation.
    3. Greater than moderate-to-severe tricuspid valve regurgitation.
    4. Greater than moderate aortic valve stenosis or regurgitation.

  17. Known hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or other infiltrative cardiomyopathy (e.g., hemochromatosis, sarcoidosis).

  18. History of clinically significant liver cirrhosis.

  19. Prior weight loss surgery

  20. Dialysis dependent; or estimated GFR <25 ml/min/1.73 m2 by CKD-EPI creatinine equation.

  21. Arterial oxygen saturation <90% on room air.

  22. Chronic pulmonary disease requiring continuous home oxygen OR hospitalization for exacerbation of chronic pulmonary disease (including intubation) in the 12 months before study entry OR known history of GOLD Class III or worse chronic obstructive pulmonary disease (COPD).

  23. Participating in conflicting investigational drug or device study that is not completed within 30 days prior to the screening visit.

  24. Life expectancy <12 months for non-cardiovascular reasons.

  25. Any condition, or history of illness or surgery that, in the opinion of the site investigator or Screening Committee, might confound the results of the study or pose additional risks to the patient.

  26. Females who are pregnant or lactating or planning to become pregnant during the next year.

  27. Any of the following measured by screening right heart catheterization:

    1. Mean right atrial pressure (RAP) >20 mmHg at rest
    2. Cardiac index <2.0 L/min/m2 at rest
    3. Pulmonary vascular resistance (PVR) >4 Wood units

    Exclusion Criteria Assessed During the index procedure:

  28. Vessel tortuosity or variant vascular anatomy that could preclude the access or maneuvering of the interventional device from the access site to target vessel. This includes previous spine surgery that may impact the ability to access and treat the target sites of T11 and T10.

Учебный план

В этом разделе представлена ​​подробная информация о плане исследования, в том числе о том, как планируется исследование и что оно измеряет.

Как устроено исследование?

Детали дизайна

  • Основная цель: Уход
  • Распределение: Рандомизированный
  • Интервенционная модель: Параллельное назначение
  • Маскировка: Двойной

Оружие и интервенции

Группа участников / Армия
Вмешательство/лечение
Активный компаратор: Greater Splanchnic Nerve Ablation

After anesthesia is given, doctors will use the Satera Ablation System to reach a nerve called the right greater splanchnic nerve. Subjects receive catheter-based unilateral ablation of the right greater splanchnic nerve.
Устройство: Greater Splanchnic Nerve Ablation

The greater splanchnic nerve (GSN) ablation procedure begins with a small needle puncture in the groin or neck to access a vein, using methods that are commonly used for heart procedures. Doctors then guide thin tubes and wires through the vein to reach a nerve called the right greater splanchnic nerve. X-ray imaging is used to help the doctor see where the catheter is and guide it to the correct location. Once the catheter is in the right place, the doctor uses the device to treat the nerve using controlled heat.
Фальшивый компаратор: Sham Control Arm

After anesthesia is given, doctors will place a small tube into a vein. The steps and length of the procedure will be similar to the Axon treatment procedure, but the study treatment will not be performed.
Устройство: Sham Control

During the sham procedure, a small needle puncture will be made in the groin or neck to access a vein using standard medical techniques. A short tube will be placed into the vein, similar to what is done for many heart procedures. The Satera catheter and treatment devices will not be inserted, and the nerve will not be treated. The procedure will take about the same amount of time as the treatment procedure.

Что измеряет исследование?

Первичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Primary Safety Endpoint: Device or procedure related serious adverse events
Временное ограничение: 1 Month

Evaluation of device or procedure-related serious adverse events at 1-month follow-up based on Clinical Events Committee (CEC) assessment
1 Month
Primary Efficacy Endpoint: KCCQ (6 months)
Временное ограничение: Baseline through 6-months

Assessment of change in Kansas City Cardiomyopathy Questionnaire (KCCQ) from baseline to 6-month follow up visit
Baseline through 6-months
Primary Efficacy Endpoint: 6MWT (6 months)
Временное ограничение: Baseline through 6 months

Assessment of change in Six Minute Walk Test (6MWT) from baseline to the 6-month follow up visit
Baseline through 6 months

Вторичные показатели результатов

Мера результата
Мера Описание
Временное ограничение
Pulmonary Capillary Wedge Pressure (PCWP)
Временное ограничение: Baseline through 1-month

Change in pulmonary capillary wedge pressure (PCWP) at resting, legs up, 20 Watts, and Peak Exercise Stage from Baseline to the 1-month follow up visit
Baseline through 1-month
Stress blood volume
Временное ограничение: Baseline through 1-month

Change in estimated stress blood volume at resting, legs up, 20Watts, and Peak Exercise Stage from Baseline to the 1-month follow up visit.
Baseline through 1-month
NT-proBNP
Временное ограничение: Baseline through 24-months

Change in NT-proBNP levels from Baseline through the 24-month visit
Baseline through 24-months
KCCQ (24-months)
Временное ограничение: Baseline through 24-months

Change in KCCQ scores from baseline through the 24-month visit
Baseline through 24-months
6MWT (24-months)
Временное ограничение: Baseline through 24-months

Change in 6MWT from Baseline through the 24-month visit
Baseline through 24-months
Time to first heart failure event
Временное ограничение: Treatment through 24-months

Time to first heart failure event (hospitalizations and worsening heart failure events) through the 24-month visit
Treatment through 24-months
Incidence of heart failure events
Временное ограничение: Treatment through 24-months

Incidence of heart failure events (hospitalizations and worsening heart failure events) through the 24-month visit
Treatment through 24-months
Hierarchical composite endpoint (12-months)
Временное ограничение: Baseline through 12-months

Composite endpoint of cardiovascular death, heart failure events, and changes in KCCQ from Baseline to the 12-month visit
Baseline through 12-months
Incidence of serious device related cardiac or vascular events
Временное ограничение: Treatment through 12- and 24-months

Assessment of the incidence of serious device related cardiac or vascular events through 12- and 24-months
Treatment through 12- and 24-months
Device or procedure related pain
Временное ограничение: Treatment through 24-months

Assessment of device or procedure related pain lasting at least 30 days and requiring medical management
Treatment through 24-months
Orthostatic hypotension
Временное ограничение: Treatment through 12- and 24-months

Incidence of new orthostatic hypotension up to 12- and 24-months
Treatment through 12- and 24-months
Acute Kidney Injury (AKI)
Временное ограничение: Baseline through 12-and 24-months

Incidence of AKI requiring renal replacement therapy up to 12- and 24-months
Baseline through 12-and 24-months
Glomerular Filtration Rate (GFR)
Временное ограничение: Baseline through 12- and 24-months

Incidence of worsening GFR (defined as >50% for at least 30 days in duration) up to 12- and 24-months
Baseline through 12- and 24-months
Adverse Events
Временное ограничение: Procedure through 12- and 24-months

Incidence of all Adverse Events through 12- and 24-months
Procedure through 12- and 24-months
Mortality
Временное ограничение: Procedure through 6-, 12- and 24-months

Incidence of all mortality for up to 6-, 12-, and 24-months summarized as all-cause mortality, CV mortality, or heart failure-related
Procedure through 6-, 12- and 24-months

Другие показатели результатов

Мера результата
Мера Описание
Временное ограничение
Exploratory endpoint: Heart failure related medication changes (24-months)
Временное ограничение: Baseline through 24-months

Freedom from heart failure related medication changes through the 24-month visit
Baseline through 24-months
Exploratory Endpoint: Diuretic medication (24-months)
Временное ограничение: Baseline through 24-months

Change in diuretic dose through the 24-month visit
Baseline through 24-months
Exploratory Endpoint: Diastolic function (24-months)
Временное ограничение: Baseline through 24-months

Assessment of diastolic function by transthoracic echocardiography evaluated over time from baseline through 24-months
Baseline through 24-months
Exploratory Endpoint: C-reactive protein
Временное ограничение: Baseline through 24-months

Change in c-reactive protein levels from Baseline through 24-months
Baseline through 24-months
Exploratory Endpoint: Aldosterone (ALD)
Временное ограничение: Baseline through 24-months

Change in aldosterone levels from Baseline through 24-months
Baseline through 24-months
Exploratory Endpoint: Renin
Временное ограничение: Baseline through 24-months

Change in Renin levels from Baseline through 24-months
Baseline through 24-months
Exploratory Endpoint: Weight
Временное ограничение: Baseline through 24-months

Change in weight from Baseline through 24-months
Baseline through 24-months

Соавторы и исследователи

Здесь вы найдете людей и организации, участвующие в этом исследовании.

Спонсор

Axon Therapies, Inc.

Соавторы

Northwestern University
NAMSA
Cardiovascular Research Foundation, New York

Следователи

  • Главный следователь: Sanjiv S Shah, MD, Northwestern University

Публикации и полезные ссылки

Лицо, ответственное за внесение сведений об исследовании, добровольно предоставляет эти публикации. Это может быть что угодно, связанное с исследованием.

Общие публикации

Даты записи исследования

Эти даты отслеживают ход отправки отчетов об исследованиях и сводных результатов на сайт ClinicalTrials.gov. Записи исследований и сообщаемые результаты проверяются Национальной медицинской библиотекой (NLM), чтобы убедиться, что они соответствуют определенным стандартам контроля качества, прежде чем публиковать их на общедоступном веб-сайте.

Изучение основных дат

Начало исследования (Действительный)

18 декабря 2020 г.

Первичное завершение (Оцененный)

10 января 2028 г.

Завершение исследования (Оцененный)

10 августа 2029 г.

Даты регистрации исследования

Первый отправленный

7 октября 2020 г.

Впервые представлено, что соответствует критериям контроля качества

13 октября 2020 г.

Первый опубликованный (Действительный)

19 октября 2020 г.

Обновления учебных записей

Последнее опубликованное обновление (Действительный)

21 сентября 2026 г.

Последнее отправленное обновление, отвечающее критериям контроля качества

16 сентября 2026 г.

Последняя проверка

1 сентября 2026 г.

Дополнительная информация

Термины, связанные с этим исследованием

Ключевые слова

Другие идентификационные номера исследования

  • 09868

Планирование данных отдельных участников (IPD)

Планируете делиться данными об отдельных участниках (IPD)?

НЕТ

Информация о лекарствах и устройствах, исследовательские документы

Изучает лекарственный продукт, регулируемый FDA США.

Нет

Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.

Да

Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .

Подписаться